科研之友
微信
新浪微博
Facebook
分享链接
摘要
Objective To explore the efficacy of subcutaneous injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in preventing invasive fungal disease (IFD) in patients with multiple myeloma (MM). Methods The clinical data of 222 patients who were admitted to the Second Hospital of Harbin Medical University from January 2015 to June 2021 were retrospectively analyzed. The patients was given GM-CSF (3-5 μg·kg-1·d-1, GM-CSF group) or granulocyte colony-stimulating factor (G-CSF, 2-5 μg·kg-1·d-1, G-CSF group) when neutrophils (ANC) ≤1.5×109/L after induction chemotherapy. Patients were discontinued when white blood cell count (WBC) ≥10.0×109/L. The incidence of IFD (including confirmed, clinical and proposed diagnosis) and breakthrough invasive fungal infections was compared between the two groups. Results The incidence of IFD was 8.1% (18/222) in all patients. The incidence of IFD was 3.5% (3/85) and 10.9% (15/137) in the GM-CSF and G-CSF groups, respectively, and the difference between the two groups was statistically significant (χ2 = 3.88, P = 0.049). In 9 patients of GM-CSF group receiving fungal infection prophylaxis and in 15 patients of G-CSF group receiving fungal infection prophylaxis, the incidence of breakthrough invasive fungal infections was 0 and 7 cases, respectively, and the difference between the two groups was statistically significant (P = 0.022). Conclusions GM-CSF application in MM patients can reduce the incidence of IFD and breakthrough invasive fungal infections. ? 2023 Chinese Medical Journal Publishing House Co. Ltd.
- 单位
